12
nov
-
14
nov
Porte de Versailles
- Heavent Paris 2024Access TCA was tasked with creating an eye catching, engaging, brand experience for the premier of Novartis' breakthrough new heart failure drug: Entresto.
“Our design was meant to be a 3 dimensional embodiment of the Entresto brand itself. In addition to the premier of this new therapy at AHA 2015 there was also a disease state component to the exhibit aimed at further educating healthcare professionals on the risk factors associated with heart disease.”
Project info | |
---|---|
Catégorie | Construction des stands |
Client | Access TCA (USA) |
Correct | AHA 2015 |
Copyright © 2024 beMatrix. Tous droits réservés. Cookie policy - Politique de confidentialité - Conditions - Conditions de location